[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355997-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355997-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plasma-herv-k-envelope-rna-a-minimally-invasive-biomarker-for-lung-adenocarcinoma-detection-and-prognostic-assessment-in-the-context-of-conventional-serum-tumor-markers","Plasma HERV-K envelopE RNA - a minimally invasive biomarker for lung adenocarcinoma detection and prognostic assessment in the context of conventional serum tumor markers","","Early detection of lung adenocarcinoma (LUAD) remains difficult due to high false-positive rates from low-dose computed tomography and limited, histology-dependent performance of conventional serum tumor markers. This retrospective single-center study evaluated whether plasma HERV-K env mRNA can support subtype-specific diagnosis and prognostic assessment in lung cancer. Plasma levels distinguished lung cancer from benign nodules and controls, showed tissue concordance, and provided independent prognostic value in LUAD.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plasma-herv-k-envelope-rna-a-minimally-invasive-biomarker-for-lung-adenocarcinoma-detection-and-prognostic-assessment-in-the-context-of-conventional-serum-tumor-markers/355997/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plasma-herv-k-envelope-rna-a-minimally-invasive-biomarker-for-lung-adenocarcinoma-detection-and-prognostic-assessment-in-the-context-of-conventional-serum-tumor-markers/355997.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study evaluated plasma HERV-K env mRNA for lung cancer?","Question",{"text":63,"@type":64},"A retrospective single-center study investigated whether plasma HERV-K env mRNA can serve as a minimally invasive biomarker for subtype-specific diagnosis and prognostic assessment in lung cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was HERV-K env mRNA measured and which groups were included?",{"text":68,"@type":64},"HERV-K env mRNA was quantified by qRT-PCR in tumor tissues, paired adjacent tissues, and EDTA-anticoagulated plasma. The cohort included non-small cell lung cancer patients (including LUAD and LUSC), malignant and benign pulmonary nodules, and healthy controls.",{"name":70,"@type":61,"acceptedAnswer":71},"Does plasma HERV-K env mRNA correlate with conventional serum tumor markers?",{"text":72,"@type":64},"The study reported no significant correlations between plasma HERV-K env mRNA and conventional serum tumor markers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355997,1790648834,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 01 July 2026  \nDOI 10.3389/fimmu.2026.1782414  \nOPEN ACCESS  \nEDITED BY  \nZhenwei Shi,  \nGuangdong Academy of Medical Sciences, China  \nREVIEWED BY  \nXinhao Peng,  \nUniversity of Electronic Science and Technology of China, China  \nYiluo Xie,  \nBengbu Medical College, China  \n*CORRESPONDENCE  \nZhi-Qiang Ling  \n [lingzq@zjcc.org.cn](lingzq@zjcc.org.cn)  \nRECEIVED 07 January 2026  \nREVISED 05 June 2026  \nACCEPTED 15 June 2026  \nPUBLISHED 01 July 2026  \nCITATION  \nBu F, Jin Z-Y and Ling Z-Q (2026) Plasma HERV-K envelopE RNA: a minimally invasive biomarker for lung adenocarcinoma detection and prognostic assessment in the context of conventional serum tumor markers. Front. Immunol. 17:1782414 .  \ndoi: 10.3389/fimmu.2026.1782414  \nCOPYRIGHT  \n© 2026 Bu, Jin and Ling. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPlasma HERV-K envelopE RNA: a minimally invasive biomarker for lung adenocarcinoma detection and prognostic assessment in the context of conventional serum tumor markers  \nFan Bu 1,2, Zi-Yan Jin1 and Zhi-Qiang Ling 1,2*  \n1Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China, 2The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, China  \nIntroduction: Early detection of lung adenocarcinoma (LUAD) remains challenging because low-dose computed tomography produces many falsepositive pulmonary nodules and conventional serum tumor markers show histology-dependent diagnostic performance. We investigated whether plasma HERV-K env mRNA could serve as a minimally invasive biomarker for subtypespeciﬁc diagnosis and prognostic assessment in lung cancer.  \nMethods: This retrospective single-center study enrolled 379 subjects, including 249 patients with non-small cell lung cancer (162 LUAD and 87 lung squamous cell carcinoma [LUSC]), 30 patients with malignant pulmonary nodules, 50 patients with benign pulmonary nodules, and 50 healthy controls. HERV-K env mRNA was quantiﬁed in tumor tissues, paired adjacent tissues, and EDTAanticoagulated plasma by qRT-PCR. Associations with clinicopathological variables, tissue-plasma concordance, correlations with conventional serum tumor markers, ROC diagnostic performance, Kaplan-Meier survival, and multivariable Cox regression were analyzed.  \nResults: HERV-K env mRNA was signiﬁcantly upregulated in NSCLC tissues versus paired adjacent tissues (P \u003C 0.0001) and was higher in LUAD than in LUSC (P \u003C 0. 0001) . Tissue expression increased with advanced T stage, lymph node metastasis, and higher TNM stage (all P \u003C 0 . 0001) . Plasma HERV-K env mRNA levels were signiﬁcantly elevated in lung cancer compared with benign pulmonary nodules and healthy controls (P \u003C 0.0001) and correlated strongly with tissue expression in both LUSC (r = 0 . 9025) and LUAD (r = 0 .7305) . ROC analysis showed excellent performance for stage I/II LUAD versus healthy controls (AUC = 0.914), moderate performance for malignant pulmonary nodules versus healthy controls (AUC = 0 .758), but limited performance for early-stage LUSC (AUC = 0 . 505) . Plasma HERV-K env mRNA showed no signiﬁcant correlations with conventional serum tumor markers. High plasma HERV-K env mRNA was associated with poorer overall survival in LUAD (P = 0.035), and multivariable Cox regression supported independent prognostic value in the overall cohort.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nDiscussion: Plasma HERV-K env mRNA captures a biologically plausible and analytically non-redundant signal with the strongest current clinical pro","cbCaieYDD2SbGR26","https://ap.wps.com/l/cbCaieYDD2SbGR26","pdf",2188210,12,"English","# Introduction\n# Methods\n# Results\n# Discussion\n# Keywords","[{\"question\":\"What study evaluated plasma HERV-K env mRNA for lung cancer?\",\"answer\":\"A retrospective single-center study investigated whether plasma HERV-K env mRNA can serve as a minimally invasive biomarker for subtype-specific diagnosis and prognostic assessment in lung cancer.\"},{\"question\":\"How was HERV-K env mRNA measured and which groups were included?\",\"answer\":\"HERV-K env mRNA was quantified by qRT-PCR in tumor tissues, paired adjacent tissues, and EDTA-anticoagulated plasma. The cohort included non-small cell lung cancer patients (including LUAD and LUSC), malignant and benign pulmonary nodules, and healthy controls.\"},{\"question\":\"Does plasma HERV-K env mRNA correlate with conventional serum tumor markers?\",\"answer\":\"The study reported no significant correlations between plasma HERV-K env mRNA and conventional serum tumor markers.\"}]","Plasma HERV-K envelopE RNA - a minimally invasive biomarker for lung adenocarcinoma detection and prognostic assessment in the context of conventional serum tumor markers | PDF",1790122210,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ed505c15b74d4061f3b0a4b652792e6.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66fbe8539626d65882d8a98c397bb543.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76f0ef3d6abf8641028184e3394cc929.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b80fc407c5b68d3313e71f4b08bc52e8.webp",980,1385]